 Home > Biochemistry News > Biotechnology News > More than half of the patients' skin symptoms improved by more than 75%. Eli Lilly's eczema antibody therapy reached the phase 3 clinical endpoint

More than half of the patients' skin symptoms improved by more than 75%. Eli Lilly's eczema antibody therapy reached the phase 3 clinical endpoint

 Last Update: 2021-09-05
 Source: Internet
 Author: User

Tags

source safety

octreotide mechanism action

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 16, 2021, Eli Lilly and Company announced that lebrikizumab, a monoclonal antibody therapy targeting IL-13, has reached the primary endpoint in two pivotal Phase 3 clinical trials ADvocate 1 and ADvocate 2 And all key secondary endpoints

Atopic dermatitis, also known as eczema, is a chronic inflammatory skin disease caused by skin barrier dysfunction and immune response disorders

Lebrikizumab is an innovative monoclonal antibody drug that can bind IL-13 with high affinity and high specificity, thereby preventing the formation of IL-13Rα1/IL-4Rα complex and inhibiting the receptor complex-mediated Signal pathway

▲The mechanism of action of Lebrikizumab and other antibody therapies targeting IL-4 and IL-13 signaling pathways (picture source: reference [2])

In terms of safety, during the initial 16-week control period, the incidence of adverse events (AE) and serious AEs after lebrikizumab treatment was consistent with previous studies

Reference materials:

[1] Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials.

[2] Moyle et al.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.